Assessment of multi-modal magnetic resonance imaging for glioma based on a deep learning reconstruction approach with the denoising method
Acta Radiologica · 2024
DOI: 10.1177/02841851241273114 ↗Kurz gefasst
Fachartikel in der Zeitschrift Acta Radiologica, 2024. Verfasst von Jun Sun und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Beijing Tiantan Hospital, Capital Medical University, Beijing, PR China. Hauptthemen laut MEDLINE: Glioma, Deep Learning, Brain Neoplasms, Magnetic Resonance Imaging. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: Beijing Hospital Management Center Young Talents, China Postdoctoral Science Foundation, Capital Health Development Research Project.
Abstract (Originalsprache)
Background
Deep learning reconstruction (DLR) with denoising has been reported as potentially improving the image quality of magnetic resonance imaging (MRI). Multi-modal MRI is a critical non-invasive method for tumor detection, surgery planning, and prognosis assessment; however, the DLR on multi-modal glioma imaging has not been assessed.
Purpose
To assess multi-modal MRI for glioma based on the DLR method. Material and Methods We assessed multi-modal images of 107 glioma patients (49 preoperative and 58 postoperative). All the images were reconstructed with both DLR and conventional reconstruction methods, encompassing T1-weighted (T1W), contrast-enhanced T1W (CE-T1), T2-weighted (T2W), and T2 fluid-attenuated inversion recovery (T2-FLAIR). The image quality was evaluated using signal-to-noise ratio (SNR), contrast-to-noise ratio (CNR), and edge sharpness. Visual assessment and diagnostic assessment were performed blindly by neuroradiologists.
Results
In contrast with conventionally reconstructed images, (residual) tumor SNR for all modalities and tumor to white/gray matter CNR from DLR images were higher in T1W, T2W, and T2-FLAIR sequences. The visual assessment of DLR images demonstrated the superior visualization of tumor in T2W, edema in T2-FLAIR, enhanced tumor and necrosis part in CE-T1, and fewer artifacts in all modalities. Improved diagnostic efficiency and confidence were observed for preoperative cases with DLR images.
Conclusion
DLR of multi-modal MRI reconstruction prototype for glioma has demonstrated significant improvements in image quality. Moreover, it increased diagnostic efficiency and confidence of glioma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiology, Beijing Tiantan Hospital, Capital Medical University, Beijing, PR China.
- Tiantan Image Research Center, China National Clinical Research Center for Neurological Diseases, Beijing, PR China.
- Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, PR China.
ORCID-Profile: Yaou Liu
Förderung
- Beijing Hospital Management Center Young Talents
- China Postdoctoral Science Foundation
- Capital Health Development Research Project
- Radiographic Standard Database Construction Project
- SKY Imaging Research Fund of China Foundation for International Medical Exchange
Zitieren
APA
Sun, J., Xu, S., Guo, Y., Ding, J., Zhuo, Z., Zhou, D., & Liu, Y. (2024). Assessment of multi-modal magnetic resonance imaging for glioma based on a deep learning reconstruction approach with the denoising method. Acta Radiologica. https://doi.org/10.1177/02841851241273114
Vancouver
Sun J, Xu S, Guo Y, Ding J, Zhuo Z, Zhou D, et al. Assessment of multi-modal magnetic resonance imaging for glioma based on a deep learning reconstruction approach with the denoising method. Acta Radiologica. 2024. doi:10.1177/02841851241273114
BibTeX
@article{Sun2024,
author = {Sun, Jun and Xu, Siyao and Guo, Yiding and Ding, Jinli and Zhuo, Zhizheng and Zhou, Dabiao and Liu, Yaou},
title = {Assessment of multi-modal magnetic resonance imaging for glioma based on a deep learning reconstruction approach with the denoising method},
journal = {Acta Radiologica},
year = {2024},
doi = {10.1177/02841851241273114}
}
EUVIMED